Try our Advanced Search for more refined results
Gilead Sciences, Inc. v. Merck & Co, Inc. et al
Case Number:
5:13-cv-04057
See also:
Court:
Nature of Suit:
Judge:
Firms
- Cooley LLP
- Dechert LLP
- Fish & Richardson
- Fried Frank
- Gibson Dunn
- Groombridge Wu
- Hughes Hubbard
- McCurdy Laud
- Morrison Foerster
- Sidley Austin
- Squire Patton
- Williams & Connolly
Companies
Sectors & Industries:
-
July 17, 2017
Gilead Wins $14M In Attys' Fees For Merck Patent Misconduct
A California federal judge on Friday ordered Merck & Co. Inc. to pay Gilead Sciences Inc. $14 million in attorneys' fees after finding last year that Merck committed "numerous unconscionable acts" in a patent suit against Gilead that led her to wipe out a $200 million jury verdict.
-
August 11, 2016
Gilead Entitled To Fees Over Merck Misconduct, Judge Says
Gilead Sciences may seek attorneys' fees from Merck & Co. Inc. to repair the cost of litigating an "exceptional" patent infringement case that resulted in the reversal of a $200 million jury award for Merck based on litigation misconduct, a California federal judge ruled Thursday.
-
August 04, 2016
Gilead's $15M Fee Bid On Table After Merck Witness' Lies
A California federal judge indicated Thursday that Gilead's request for $15.5 million in attorneys' fees is on the table following the reversal of a $200 million jury award for Merck in March, after it was found a company witness lied at a patent infringement trial over an ingredient in hepatitis C drugs.
-
July 20, 2016
Merck Asks To Wait For Fed. Circ. In Gilead Atty Fees Row
The Federal Circuit needs to decide whether a California federal judge was right to overturn a jury’s $200 million verdict in favor of Merck & Co. in a patent dispute over hepatitis C drugs before the judge can decide on Gilead’s $15.5 million attorneys’ fees request, Merck said Tuesday.
-
July 06, 2016
Gilead Wants $15.5M In Fees From Merck After Hep C Upset
Gilead Sciences Inc. told a California federal court Tuesday that Merck & Co. Inc. should have to hand over $15.5 million in attorneys' fees following a judge's decision that the latter company's trial misconduct was grounds to overturn a $200 million jury verdict in a patent dispute over hepatitis C drugs.
-
July 05, 2016
After Verdict Reversal, Gilead Takes Aim At Merck Patents
Gilead Sciences Inc. reasserted its position Tuesday that two Merck & Co. Inc. patents covering an ingredient in Gilead's hepatitis C drugs are invalid, a month after a California federal judge reversed Merck's $200 million jury verdict on unenforceability grounds after concluding its key witness lied.
-
June 07, 2016
Merck Atty's Lies Unravel $200M Patent Win Against Gilead
Merck forfeited its right to enforce two patents covering an ingredient in hepatitis C drugs against rival Gilead due to "numerous unconscionable acts" before and during trial, a California federal judge ruled Monday in a stunning takedown of the drugmaker's $200 million March jury verdict.
-
April 29, 2016
Gilead OK'd To Show Merck Atty Lied In $200M Patent Win
A California federal judge ruled Friday that Gilead can reopen the record following a jury's $200 million patent infringement verdict against it and admit more evidence to show a Merck attorney lied to access Gilead's confidential information, saying a fuller record will help her decide whether Merck has unclean hands.
-
April 28, 2016
Merck Says Gilead Is Exploiting Atty 'Lie' In $200M Jury Loss
Merck on Wednesday escalated a war of words with Gilead over accusations that a Merck attorney lied during a deposition over accessing confidential information, saying its biopharmaceutical rival wants to "exploit" the allegation as a "get-out-of-jail-free card" after a California's federal jury's recent $200 million damages award in the patent infringement case.
-
March 31, 2016
Gilead Says Atty's Lie Kills Merck IP Behind $200M Jury Win
Two patents behind Merck's $200 million jury trial victory last week are unenforceable, rival Gilead told a California federal judge at a follow-on bench trial Wednesday, saying an attorney who prosecuted one of Merck's hepatitis C drug patents lied in the process, tainting both patents.